RAMB - AGOSTO 2017

68 / 70

PSA screening for prostate cancer
Rev Assoc Med B ras 2017; 63(8):722-725 725
Resumo
Rastreamento do câncer de próstata com PSA
O rastreamento do câncer de próstata com antígeno pros-
tático específico (PSA) é uma questão altamente contro-
versa. Parte da polêmica se deve à confusão entre rastrea-
mento populacional e diagnóstico precoce, e outra parte
está ligada a problemas relacionados à qualidade dos
estudos de rastreamento recentes, a resultados do trata-
mento curativo radical para tumores de baixo grau ou em
estágio precoce, e a complicações advindas de tratamen-
tos que afetam a qualidade de vida do paciente. Nossa
revisão teve como objetivo analisar criticamente as reco-
mendações atuais para o teste de PSA, com base em dados
obtidos da reavaliação de estudos em andamento e na
recomendação atualizada do USPSTF, e propor o uso
mais racional e seletivo do PSA comparado a níveis iniciais
obtidos em uma idade aproximada de 40 a 50 anos.
Palavras-chave: PSA, câncer de próstata, rastreamento,
próstata.
References
1. INCA. Tipos de câncer. Próstata [cited 2017 Jul 18]. Available from: http://
2. Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental
prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;
137(7):1749-57.
3. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA;
Grading Committee. The 2014 International Society of Urological Pathology
(ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma:
definition of grading patterns and proposal for a new grading system. Am
J Surg Pathol. 2016; 40(2):244-52.
4. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE. Time trends
in clinical risk stratification for prostate cancer: implications for outcomes
(data from CaPSURE). J Urol. 2003; 170(6 Pt 2):S21-5.
5. Welch HG, Gorski DH, Albertsen PC. Trends in metastatic breast and prostate
cancer: Lessons in cancer dynamics. N Engl J Med. 2015; 373(18):1685-7.
6. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, et al. Screening
decreases prostate cancer death: first analysis of the 1988 Quebec prospective
randomized controlled trial. Prostate. 1999; 38(2):83-91.
7. Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. Clinical
consequences of screening for prostate cancer: 15 years follow-up of a
randomised controlled trial in Sweden. Eur Urol. 2004; 46(6):717-23.
8. Ilic D, O’Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane
systematic review. Cancer Causes Control. 2007; 18(3):279-85.
9. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et
al.; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-
up. N Engl J Med. 2012; 366(11):981-90.
10. Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van
Schaik RH, et al.; ERSPC Rotterdam Study Group. Screening for prostate
cancer: results of the Rotterdam section of the European randomized study
of screening for prostate cancer. Eur Urol. 2013; 64(4):530-9.
11. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et
al.; PLCO Project Team. Mortality results from a randomized prostate-
cancer screening trial. N Engl J Med. 2009; 360(13):1310-9.
12. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al.
Mortality results from the Göteborg randomised population-based prostate-
cancer screening trial. Lancet Oncol. 2010; 11(8):725-32.
13. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer:
U.S. Preventive Services Task Force recommendation statement. Ann Intern
Med. 2012; 157(2):120-34.
14. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson
WJ, Brawer MK. Follow-up of prostatectomy versus observation for early
prostate cancer. N Engl J Med. 2017; 377(2):132-142.
15. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL,
et al. Prevalence of prostate cancer among men with a prostate-specific anti-
gen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46.
16. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al.
Early detection of prostate cancer: AUA Guideline. J Urol. 2013; 190(2):419-26.
17. Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, et al.
Strategy for detection of prostate cancer based on relation between prostate
specific antigen at age 40-55 and long term risk of metastasis: case-control
study. BMJ. 2013; 346:f2023.
18. Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services
Task Force 2017 draft recommendation statement on screening for prostate
cancer: an invitation to review and comment. JAMA. 2017; 317(19):1949-50.
19. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et
al.; ProtecT Study Group. 10-year outcomes after monitoring, surgery,
or radiotherapy for localized prostate cancer. N Engl J Med. 2016;
375(15):1415-24.
20. Sociedade Brasileira de Urologia. NOTA OFICIAL – Rastreamento do Câncer
de Próstata. 2016 [cited 2017 Jul 18]. Available from: http://portaldaurologia.